Vir Biotechnology

Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B

Retrieved on:

Wednesday, April 21, 2021

This is the first clinical trial in the field to evaluate the combination of these two HBV mechanisms of action.\nThis press release features multimedia.

Key Points:

This is the first clinical trial in the field to evaluate the combination of these two HBV mechanisms of action.\nThis press release features multimedia.
Both agents have demonstrated proof of mechanism in HBV patients ( NCT04507269 BRII-835 China study and ACTRN12619001210167 BRII-179 APEC study).
Data from our previous study suggest BRII-179 (VBI-2601) was able to restimulate both antibody and T cell responses specific to HBV.
Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus.

Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B

Retrieved on:

Wednesday, April 21, 2021

Both agents have demonstrated proof of mechanism in HBV patients ( NCT04507269 BRII-835 China study and ACTRN12619001210167 BRII-179 APEC study).

Key Points:

Both agents have demonstrated proof of mechanism in HBV patients ( NCT04507269 BRII-835 China study and ACTRN12619001210167 BRII-179 APEC study).
Data from our previous study suggest BRII-179 (VBI-2601) was able to restimulate both antibody and T cell responses specific to HBV.
VIR-2218 is the first asset in the Company\xe2\x80\x99s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.
Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus.

Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus

Retrieved on:

Tuesday, January 12, 2021

We are enthusiastic about this collaboration, said Phil Pang, MD, PhD, Chief Medical Officer of Vir Biotechnology.

Key Points:

We are enthusiastic about this collaboration, said Phil Pang, MD, PhD, Chief Medical Officer of Vir Biotechnology.
We believe that this collaboration with Gilead adds a novel and significant new combination to our efforts to find a cure for HBV.
VEMLIDY is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.
Its current development pipeline consists of product candidates targeting SARS-CoV-2, hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis.

Vir and Alnylam Identify RNAi Therapeutic Development Candidate, VIR-2703 (ALN-COV), Targeting SARS-CoV-2 for the Treatment of COVID-19

Retrieved on:

Monday, May 4, 2020

With this DC selection, Vir and Alnylam will work closely together to generate the data required to enable rapid commencement of clinical studies.

Key Points:

With this DC selection, Vir and Alnylam will work closely together to generate the data required to enable rapid commencement of clinical studies.
Our fruitful and expansive collaboration with Alnylam has rapidly led to identification of a development candidate targeting SARS-CoV-2, said George Scangos, Ph.D., CEO of Vir.
Im very proud of the quality and pace of work done by our scientists and with our collaborators at Vir to identify an RNAi therapeutic development candidate targeting the SARS-CoV-2 genome.
VIR-2703 is the first development candidate selected in the companys expanded collaboration with Alnylam for up to four RNAi potential therapeutics for COVID-19.

Generation Bio and Vir Biotechnology to Collaborate on Research to Leverage Scalable Non-Viral Gene Therapy Platform for Durable Production of Monoclonal Antibodies Against Coronavirus That Causes COVID-19

Retrieved on:

Monday, March 30, 2020

Together, we believe we can develop long-lasting therapies suitable for population-wide prevention and treatment, said Generation Bio President and CEO Geoff McDonough, M.D.

Key Points:

Together, we believe we can develop long-lasting therapies suitable for population-wide prevention and treatment, said Generation Bio President and CEO Geoff McDonough, M.D.
We are moving with urgency to explore leveraging our platform to build protection against COVID-19 for the long term.
Generation Bios proprietary non-viral gene therapy platform is designed to enable production of target proteins from a patients own cells.
In addition, the companies intend to leverage Generation Bios scalable manufacturing process to potentially extend the reach of Virs monoclonal antibodies to a greater number of patients.

Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19

Retrieved on:

Wednesday, March 4, 2020

The collaboration will focus on development of siRNAs that Alnylam recently identified that target highly conserved regions of coronavirus RNAs.

Key Points:

The collaboration will focus on development of siRNAs that Alnylam recently identified that target highly conserved regions of coronavirus RNAs.
Alternatively, Alnylam may elect to earn development and commercialization milestones and royalties on net sales of products resulting from the collaboration in amounts agreed upon for the coronavirus program.
RNAi is a powerful, natural cellular mechanism that can be harnessed to develop a broad range of innovative medicines, including anti-viral therapies.
As the leader in RNAi therapeutics, we at Alnylam are committed to doing our part in joining other biopharmaceutical companies, like Vir, to address this emerging outbreak.